Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s00262-023-03534-z
Publication URI: http://dx.doi.org/10.1007/s00262-023-03534-z
Type: Journal Article/Review
Parent Publication: Cancer Immunology, Immunotherapy